Form 4: Galectin Therapeutics Director Acquires Shares in Open Market Transaction

Richard A. Zordani Jr., a director at Galectin Therapeutics, purchased 10,000 shares of common stock at $0.8164 per share on December 24, 2024.

Summary

• Richard A. Zordani Jr., a director of Galectin Therapeutics, acquired 10,000 shares of the company's common stock on December 24, 2024.
• The purchase price was $0.8164 per share.
• Following the transaction, Mr. Zordani directly owns 42,083 shares of Galectin Therapeutics common stock.
• He also indirectly owns 2,000 shares as a custodian for a minor child under the Uniform Transfer to Minors Act.
• Mr. Zordani disclaims beneficial ownership of the 2,000 shares held in custody.

Sentiment

Score: 6

Explanation: The document is a routine filing related to an insider purchase. It is neither overwhelmingly positive nor negative, but the purchase could be interpreted as a mild positive signal.

Positives

• A director's purchase of shares can be seen as a positive signal of confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Form 4 filings are a standard practice for all publicly traded companies in the US, ensuring transparency of insider trading.
• The transaction is typical for directors who may buy or sell shares in their company.

Stakeholder Impact

• The purchase may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Galectin Therapeutics, insider trading, Form 4, share purchase, director, Richard A. Zordani Jr., GALT